SCHEMBL3547476

SCHEMBL3547476

CS(=O)(=O)Oc1cccc(N)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
CYP3A4 P08684 3/20 0.55
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
TP53 P04637 1/20 0.50
MAOB P27338 2/20 0.48
LMNA P02545 1/20 0.45
CA12 O43570 1/20 0.44
CA4 P22748 1/20 0.44
CA14 Q9ULX7 1/20 0.44
TSHR P16473 2/20 0.43
POLB P06746 1/20 0.43
HSP90AA1 P07900 1/20 0.43
MAPT P10636 1/20 0.43
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CASP1 P29466 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4976619 0.98 ALDH1A1 (0.53) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL3838916 0.85 CA2 (0.60) ALDH1A1CA1CA2CA9
SCHEMBL3113873 0.83 CA1 (0.54) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL31620700 0.83 CA1 (0.54) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL11672476 0.82 CA2 (0.76) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL10693773 0.81 CYP3A4 (0.56) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL31576122 0.80 ALDH1A1 (0.52) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL8772926 0.80 CA1 (0.50) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL3381331 0.80 ALDH1A1 (0.52) ALDH1A1CYP3A4CA1CA2CA9
SCHEMBL31408860 0.80 CA1 (0.50) ALDH1A1CYP3A4CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732063-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-08-15 US disclosed
EP-2925742-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2016-10-26 EP disclosed
US-20150329523-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2015-11-19 US disclosed
EP-2925742-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-10-07 EP disclosed
WO-2014076484-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-05-22 WO disclosed
CN-102352125-B Disperse black and blue dye composition ZHEJIANG RUNTU CO LTD 2013-08-14 CN disclosed
US-8382857-B2 Method for the reactive coloration of leather BASF SE (DE) 2013-02-26 US disclosed
US-8382857-B2 Method for the reactive coloration of leather BASF SE (DE) 2013-02-26 US disclosed
US-8372161-B2 Method for the reactive coloring of leather BASF SE (DE) 2013-02-12 US disclosed
US-8372161-B2 Method for the reactive coloring of leather BASF SE (DE) 2013-02-12 US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
EP-1487824-B1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-06-20 EP disclosed
EP-1487824-B1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-06-20 EP disclosed
US-20070033746-A1 Method for the reactive coloring of leather BASF AKTIENGESSELLSCHAFT (DE) 2007-02-15 US disclosed
US-20070033746-A1 Method for the reactive coloring of leather BASF AKTIENGESSELLSCHAFT (DE) 2007-02-15 US disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 US disclosed
EP-1487824-A1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-22 EP disclosed
WO-2003074515-A1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-12 WO disclosed
US-4042578-A POLYESTERS BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors TIE1, TEK, KDR ALDH1A1 994/4885CYP3A4 3874/4885CA1 4846/4885
US-20150329523-A1 KINASE INHIBITORS SYK, SRC, BTK ALDH1A1 4202/4885CYP3A4 2106/4885CA1 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.